News & Views
Telix CEO, Dr Christian Behrenbruch recently facilitated an international expert panel discussion at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Symposium entitled: “Ga-68 PSMA-11: Advances in Technology,…
Read more
News,
Telix is pleased to announce that Raphaël Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa…
Read more
Telix Pharmaceuticals announces the first U.S. patients have been dosed in the Company’s Phase III ZIRCON…
Read more
News,
Telix is delighted to announce that Danielle Meyrick MD has joined its executive medical team in the role of Chief Medical Officer (CMO),…
Read more
ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer imaging product using multi-Curie quantities of cyclotron-produced Gallium-68 via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target system. …
Read more
Telix has filed a New Drug Submission (NDS) with Health Canada for TLX591-CDx (Kit for the preparation…
Read more
Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field of urologic…
Read more
Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer…
Read more
Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton,…
Read more
Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography…
Read more